Hangzhou Biotest Biotech Co Ltd
SSE:688767
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
H
|
Hangzhou Biotest Biotech Co Ltd
SSE:688767
|
5.5B CNY |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
402.4B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
199.5B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
189.8B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.5B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.8B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
74.1B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.2B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -416 945.9% |
| 30th Percentile | -1.5% |
| Median | 3.5% |
| 70th Percentile | 8.9% |
| Max | 17 382.1% |
Other Profitability Ratios
Hangzhou Biotest Biotech Co Ltd
Glance View
Hangzhou Biotest Biotech Co., Ltd. engages in the research and development, production and sales of point-of-care testing (POCT) diagnostic reagents. The company is headquartered in Hangzhou, Zhejiang and currently employs 622 full-time employees. The company went IPO on 2021-09-08. The firm's products include reproductive health testing series, such as human chorionic gonadotropin testing reagent and luteinizing hormone testing reagent, and drug abuse testing series, such as morphine testing reagent and cocaine testing reagent, and infectious disease testing series, such as adenovirus testing reagent and typhoid antibody testing reagent, and tumor marker testing series, such as alpha fetoprotein detection reagent, and myocardial marker detection series, such as dimer detection reagent and myocardial series detection reagent.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Hangzhou Biotest Biotech Co Ltd is 21.4%, which is below its 3-year median of 21.6%.
Over the last 3 years, Hangzhou Biotest Biotech Co Ltd’s Net Margin has decreased from 48.2% to 21.4%. During this period, it reached a low of -4.3% on Sep 30, 2023 and a high of 48.2% on Aug 30, 2022.
